Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Validation of IMS/IMWG consensus genomic staging in Greek cohort of 1209 pts finds high-risk has inferior outcomes (median OS 44 vs 93 months; PFS 21.3 vs 36); ≥2 high-risk features = ultra-high w/ 3-fold risk of death.”
Title: Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients
Authors: Efstathios Kastritis, Charalampos Filippatos, Maria Gavriatopoulou, Foteini Theodorakakou, Eirini Solia, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Aikaterini Vlachou, Despina Fotiou, Konstantinos Giannakas, Erasmia Boutakoglou, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Evangelos Terpos, Meletios A. Dimopoulos
You can read the full article on HemaSphere.

You can find other articles featuring Robert Orlowski on OncoDaily.